Quent Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.1K Buy
319
+53
+20% +$3.34K ﹤0.01% 1099
2026
Q2
$15.2K Sell
266
-103
-28% -$5.64K ﹤0.01% 1137
2026
Q1
$20.8K Buy
369
+45
+14% +$2.62K ﹤0.01% 982
2025
Q4
$19.3K Sell
324
-202
-38% -$11K ﹤0.01% 1001
2025
Q3
$28.5K Buy
+526
New +$30.1K ﹤0.01% 759
2025
Q2
– Sell
-189
Closed -$13.4K – 400
2025
Q1
$13.4K Buy
189
+33
+21% +$2.22K ﹤0.01% 856
2024
Q4
$10.3K Sell
156
-100
-39% -$6.7K ﹤0.01% 931
2024
Q3
$18K Sell
256
-135
-35% -$11.3K ﹤0.01% 905
2024
Q2
$32.2K Buy
391
+145
+59% +$12.1K ﹤0.01% 743
2024
Q1
$21.5K Sell
246
-112
-31% -$10K ﹤0.01% 863
2023
Q4
$34.5K Buy
358
+23
+7% +$2.04K ﹤0.01% 706
2023
Q3
$29.6K Sell
335
-1,223
-78% -$109K ﹤0.01% 707
2023
Q2
$135K Buy
1,558
+23
+1% +$2.16K 0.02% 358
2023
Q1
$147K Buy
1,535
+1,374
+853% +$142K 0.03% 337
2022
Q4
$16.7K Hold
161
– – ﹤0.01% 804
2022
Q3
$14K Buy
161
+12
+8% +$1.07K ﹤0.01% 799
2022
Q2
$12K Hold
149
– – ﹤0.01% 793
2022
Q1
$11K Buy
149
+30
+25% +$2.51K ﹤0.01% 887
2021
Q4
$11K Buy
+119
New +$9.8K ﹤0.01% 803

Other funds holding BMRN

Quent Capital's BMRN Position: Q3 2026 in Review

Quent Capital increased its BioMarin Pharmaceuticals (BMRN) stake by 20% in Q3 2026, buying an estimated $3.34K and bringing the position to 319 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1099.

Quent Capital first reported a position in BMRN in Q4 2021 and has held it in 19 quarters since. The position peaked at $147K in Q1 2023. 559 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Quent Capital held 319 shares of BioMarin Pharmaceuticals worth $19.1K as of Q3 2026.
  • Quent Capital bought 53 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $3.34K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Quent Capital's portfolio in Q3 2026, its #1099 holding.
  • Quent Capital first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Quent Capital's BioMarin Pharmaceuticals position peaked at $147K in Q1 2023.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Quent Capital's 13F filing for Q3 2026, filed 9 Nov 2026.